You have full text access to this OnlineOpen article

The Impact of Chronic Hepatitis B on Quality of Life: A Multinational Study of Utilities from Infected and Uninfected Persons

  1. Adrian R. Levy PhD1,2,*,
  2. Kris V. Kowdley MD3,
  3. Uchenna Iloeje MD, MPH4,
  4. Eskinder Tafesse PhD4,
  5. Jayanti Mukherjee PhD4,
  6. Robert Gish MD5,
  7. Natalie Bzowej MD5,
  8. Andrew H. Briggs DPhil1,6

Article first published online: 17 DEC 2007

DOI: 10.1111/j.1524-4733.2007.00297.x

Issue

Value in Health

Value in Health

Volume 11, Issue 3, pages 527–538, May/June 2008

Additional Information

How to Cite

Levy, A. R., Kowdley, K. V., Iloeje, U., Tafesse, E., Mukherjee, J., Gish, R., Bzowej, N. and Briggs, A. H. (2008), The Impact of Chronic Hepatitis B on Quality of Life: A Multinational Study of Utilities from Infected and Uninfected Persons. Value in Health, 11: 527–538. doi: 10.1111/j.1524-4733.2007.00297.x

Author Information

  1. 1

    Oxford Outcomes Ltd, Vancouver, BC, Canada;

  2. 2

    University of British Columbia, Vancouver, BC, Canada;

  3. 3

    Digestive Disease Institute, Virginia Mason Medical Center, Seattle, WA, USA;

  4. 4

    Bristol-Myers Squibb Company, Wallingford, CT, USA;

  5. 5

    California Pacific Medical Center, San Francisco, CA, USA;

  6. 6

    Glasgow University, Glasgow, UK

*Adrian R. Levy, Oxford Outcomes Ltd, 450–688 West Hastings Street, Vancouver, BC, Canada V6B 1P1. E-mail: adrian.levy@oxfordoutcomes.com

Publication History

  1. Issue published online: 17 DEC 2007
  2. Article first published online: 17 DEC 2007

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (127K)

References

  • 1
    Von Neumann J, Morgenstern O. Theory of Games and Economic Behavior. Princeton, NJ: Princeton University Press, 1947.
  • 2
    Torrance GW. Measurement of health state utilities for economic appraisal. J Health Econ 1986;5:1–30.
  • 3
    Testa MA, Nackley JF. Methods for quality-of-life studies. Annu Rev Public Health 1994;15:535–59.
  • 4
    Schackman BR, Gold HT, Stone PW, Neumann PJ. How often do sensitivity analyses for economic parameters change cost-utility analysis conclusions? Pharmacoeconomics 2004;22:293–300.
  • 5
    Souchek J, Byrne MM, Kelly PA, et al. Valuation of arthritis health states across ethnic groups and between patients and community members. Med Care 2005;43:921–8.
  • 6
    Custer B, Sullivan SD, Hazlet TK, et al. Global epidemiology of hepatitis B virus. J Clin Gastroenterol 2004;38(Suppl.):S158–68.
  • 7
    Lee WM. Hepatitis B virus infection. N Engl J Med 1997;337:1733–45.
  • 8
    Fattovich G. Natural history of hepatitis B. J Hepatol 2003;39(Suppl. 1):S50–8.
  • 9
    Chen CJ, Yang HI, Su J, et al. Elevated serum level of hepatitis B virus DNA is an independent risk factor for hepatocellular carcinoma: a long-term follow-up study in Taiwan. J Hepatol 2005;42(Suppl. 2):S16–17.
  • 10
    Chen G, Lin WY, Shen FM, et al. Viral load as a predictor of mortality from hepatocellular carcinoma and chronic liver disease in chronic hepatitis B infection. J Hepatol 2005;42(Suppl. 2):S173.
  • 11
    Iloeje UH, Yang HI, Su J, et al. Viral load not serum alanine aminotransferase (ALT) is the primary predictor of progression to cirrhosis in persons chronically infected with hepatitis B virus. Gastroenterology 2005;128:A–740.
  • 12
    Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130:678–86.
  • 13
    Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127(Suppl.):S35–50.
  • 14
    Ganem D, Prince AM. Hepatitis B virus infection––natural history and clinical consequences. N Engl J Med 2004;350:1118–29.
  • 15
    Brown RE, De CE, Colin X, et al. Hepatitis B management costs in France, Italy, Spain, and the United Kingdom. J Clin Gastroenterol 2004;38(Suppl.):S169–74.
  • 16
    Butler JR, Pianko S, Korda RJ, et al. The direct cost of managing patients with chronic hepatitis B infection in Australia. J Clin Gastroenterol 2004;38(Suppl.):S187–92.
  • 17
    Gagnon YM, Levy AR, Iloeje UH, Briggs AH. Treatment costs in Canada of health conditions resulting from chronic hepatitis B infection. J Clin Gastroenterol 2004;38(Suppl.):S179–86.
  • 18
    Hsieh CR, Kuo CW. Cost of chronic hepatitis B virus infection in Taiwan. J Clin Gastroenterol 2004;38(Suppl.):S148–52.
  • 19
    Kowdley KV. The cost of managing chronic hepatitis B infection: a global perspective. J Clin Gastroenterol 2004;38(Suppl.):S132–3.
  • 20
    Lee TA, Veenstra DL, Iloeje UH, Sullivan SD. Cost of chronic hepatitis B infection in the United States. J Clin Gastroenterol 2004;38(Suppl.):S144–7.
  • 21
    Li SC, Ong SC, Lim SG, et al. A cost comparison of management of chronic hepatitis B and its associated complications in Hong Kong and Singapore. J Clin Gastroenterol 2004;38(Suppl.):S136–43.
  • 22
    Yang BM, Kim CH, Kim JY. Cost of chronic hepatitis B infection in South Korea. J Clin Gastroenterol 2004;38(Suppl.):S153–7.
  • 23
    Zhiqiang G, Zhaohui D, Qinhuan W, et al. Cost of chronic hepatitis B infection in China. J Clin Gastroenterol 2004;38(Suppl.):S175–8.
  • 24
    Mueller AR, Platz KP, Kremer B. Early postoperative complications following liver transplantation. Best Pract Res Clin Gastroenterol 2004;18:881–900.
  • 25
    Brazier J, Green C, McCabe C, Stevens K. Use of visual analog scales in economic evaluation. Expert Rev Pharmacoeconomics Outcomes Res 2003;3:293–302.
  • 26
    Torrance GW, Furlong W, Feeny D. Health utility estimation. Exp Rev Pharmacoeconom Res 2002;2:99–108.
  • 27
    Kanwal F, Gralnek IM, Martin P, et al. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Ann Intern Med 2005;142:821–31.
  • 28
    Wong JB, Koff RS, Tine F, Pauker SG. Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1995;122:664–75.
  • 29
    Arevalo JA, Washington AE. Cost-effectiveness of prenatal screening and immunization for hepatitis B virus. JAMA 1988;259:365–9.
  • 30
    Bloom BS, Hillman AL, Fendrick AM, Schwartz JS. A reappraisal of hepatitis B virus vaccination strategies using cost-effectiveness analysis. Ann Intern Med 1993;118:298–306.
  • 31
    Krahn M, Detsky AS. Should Canada and the United States universally vaccinate infants against hepatitis B? A cost-effectiveness analysis. Med Decis Making 1993;13:4–20.
  • 32
    Chong CA, Gulamhussein A, Heathcote EJ, et al. Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol 2003;98:630–8.
    Direct Link:
  • 33
    Boyd NF, Sutherland HJ, Heasman KZ, et al. Whose utilities for decision analysis? Med Decis Making 1990;10:58–67.
  • 34
    De Wit GA, Busschbach JJV, De Charro FT. Sensitivity and perspective in the valuation of health status: whose values count? Health Econ 2000;9:109–26.
    Direct Link:
  • 35
    Dolan P. Whose preferences count? Med Decis Making 1999;19:482–6.
  • 36
    Janse AJ, Gemke RJ, Uiterwaal CS, et al. Quality of life: patients and doctors don't always agree: a meta-analysis. J Clin Epidemiol 2004;57:653–61.
  • 37
    Gold MR, Siegel JE, Russel LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
  • 38
    Bennet KJ, Torrance GW. Measuring health state preferences and utilities: rating scale, time trade-off and standard gamble techniques. In: SpilkerB, ed. Quality of Life and Pharmacoeconomics in Clinical Trials. Philadelphia, PA: Lippincott-Raven, 1996.
  • 39
    Furlong W, Feeny D, Torrance GW, et al. Guide to Design and Development of Health State Utility Instrumentation. Working Paper 90-9. Hamilton, ON: McMaster University Centre for Health Economics and Policy Analysis, 1990.
  • 40
    Llewellyn-Thomas H, Sutherland HJ, Tibshirani R, et al. Describing health states. Methodologic issues in obtaining values for health states. Med Care 1984;22:543–52.
  • 41
    Schunemann HJ, Stahl E, Austin P, et al. A comparison of narrative and table formats for presenting hypothetical health states to patients with gastrointestinal or pulmonary disease. Med Decis Making 2004;24:53–60.
  • 42
    Gralnek IM, Hays RD, Kilbourne A, et al. Development and evaluation of the Liver Disease Quality of Life instrument in persons with advanced, chronic liver disease––the LDQOL 1.0. Am J Gastroenterol 2000;95:3552–65.
  • 43
    Torrance GW, Feeny D, Furlong W. Visual analog scales: do they have a role in the measurement of preferences for health states? Med Decis Making 2001;21:329–34.
  • 44
    Hoffmann JP. Generalized Linear Models: an Applied Approach. Boston, MA: Pearson Education Inc, 2004.
  • 45
    Patrick DL, Starks HE, Cain KC, et al. Measuring preferences for health states worse than death. Med Decis Making 1994;14:9–18.
  • 46
    Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2001;34:1225–41.
    Direct Link:
  • 47
    World Health Organization. Hepatitis B. World Health Organization Fact Sheet 204. 2000. Available form: http://www.who.int/mediacentre/factsheets/fs204/en/[Accessed July 23, 2007].
  • 48
    Pramoolsinsup C. Management of viral hepatitis B. J Gastroenterol Hepatol 2002;17(Suppl.):S125–45.
    Direct Link:
  • 49
    Mulley AG Jr. Assessing patients' utilities. Can the ends justify the means? Med Care 1989;27(Suppl.):S269–81.
  • 50
    Mittmann N, Trakas K, Risebrough N, Liu BA. Utility scores for chronic conditions in a community-dwelling population. Pharmacoeconomics 1999;15:369–76.
  • 51
    Hawthorne G, Osborne R. Population norms and meaningful differences for the Assessment of Quality of Life (AQoL) measure. Aust N Z J Public Health 2005;29:136–42.
    Direct Link:
  • 52
    Albrecht GL, Devlieger PJ. The disability paradox: high quality of life against all odds. Soc Sci Med 1999;48:977–88.
  • 53
    Sherbourne CD, Keeler E, Unutzer J, et al. Relationship between age and patients' current health state preferences. Gerontologist 1999;39:271–8.
  • 54
    Levine S, Feldman JJ, Elinson J. Does medical care do any good? In: MechanicD, ed. Handbook of Health, Health Care and the Health Professions. New York: The Free Press 1983.
  • 55
    Amick BC, Levine S, Tarlov AR, Walsh DC (eds). Society and Health. New York: Oxford University Press, 1994.
  • 56
    Schwartz CE, Andresen EM, Nosek MA, Krahn GL. Response shift theory: important implications for measuring quality of life in people with disability. Arch Phys Med Rehabil 2007;88:529–36.
  • 57
    Gabriel SE, Kneeland TS, Melton LJ III, et al. Health-related quality of life in economic evaluations for osteoporosis: whose values should we use? Med Decis Making 1999;19:141–8.
  • 58
    Postulart D, Adang EM. Response shift and adaptation in chronically ill patients. Med Decis Making 2000;20:186–93.
  • 59
    Sackett DL, Torrance GW. The utility of different health states as perceived by the general public. J Chronic Dis 1978;31:697–704.
  • 60
    Tsevat J, Cook EF, Green ML, et al. Health values of the seriously ill. SUPPORT investigators. Ann Intern Med 1995;122:514–20.
  • 61
    Balaban DJ, Sagi PC, Goldfarb NI, Nettler S. Weights for scoring the quality of well-being instrument among rheumatoid arthritics. A comparison to general population weights. Med Care 1986;24:973–80.
  • 62
    Jenkinson C, Gray A, Doll H, et al. Evaluation of index and profile measures of health status in a randomized controlled trial. Comparison of the Medical Outcomes Study 36-Item Short Form Health Survey, EuroQol, and disease specific measures. Med Care 1997;35:1109–18.
  • 63
    Dolders MG, Zeegers MP, Groot W, Ament A. A meta-analysis demonstrates no significant differences between patient and population preferences. J Clin Epidemiol 2006;59:653–64.
  • 64
    Dolan P. Effect of age on health state valuations. J Health Serv Res Policy 2000;5:17–21.
  • 65
    B is for bigotry. The Economist, November 16, 2006.
  • 66
    Murray CJ, Chen LC. Understanding morbidity change. Popul Dev Rev 1992;18:481–503.
  • 67
    Torrance GW. Social preferences for health states: an empirical evaluation of three measurement techniques. Socioecon Plann Sci 1976;10:128–36.
  • 68
    Kaplan RM, Bush JW, Berry CC. Health status index: category rating versus magnitude estimation for measuring levels of well-being. Med Care 1979;17:501–25.
  • 69
    Read JL, Quinn RJ, Berwick DM, et al. Preferences for health outcomes. Comparison of assessment methods. Med Decis Making 1984;4:315–29.
  • 70
    Haig TH, Scott DA, Wickett LI. The rational zero point for an illness index with ratio properties. Med Care 1986;24:113–24.
  • 71
    Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care 2000;38:583–637.
  • 72
    Wells CD, Murrill WB, Arguedas MR. Comparison of health-related quality of life preferences between physicians and cirrhotic patients: implications for cost-utility analyses in chronic liver disease. Dig Dis Sci 2004;49:453–8.
  • 73
    Bonsel GJ, Klompmaker IJ, Essink-Bot ML, et al. Cost-effectiveness analysis of the Dutch liver transplantation programme. Transplant Proc 1990;22:1481–4.
  • 74
    Kim WR, Poterucha JJ, Hermans JE, et al. Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C. Ann Intern Med 1997;127:866–74.
  • 75
    Teran JC, Imperiale TF, Mullen KD, et al. Primary prophylaxis of variceal bleeding in cirrhosis: a cost-effectiveness analysis. Gastroenterology 1997;112:473–82.
  • 76
    Owens DK, Cardinalli AB, Nease RF Jr. Physicians' assessments of the utility of health states associated with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. Qual Life Res 1997;6:77–86.
View Full Article (HTML) Get PDF (127K)